ArticleScientific reports2026
Patient-related diagnostic delay and risk of unfavorable treatment outcomes among pulmonary tuberculosis patients at the antituberculosis center of Brazzaville, Republic of Congo.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) remains a major public health concern worldwide. Early diagnosis is crucial to reduce TB transmission and improve treatment outcomes. This study assessed patient-related diagnostic delay and their impact on the treatment outcomes among pulmonary tuberculosis patients (PTB) at the Antituberculosis center in Brazzaville. We conducted a prospective cohort study from July 2023 to August 2024. Sociodemographic, clinical characteristics, patient-related diagnostic delays delay (short ≤ 30 days, prolonged > 30 days), and treatment outcomes were recorded. Logistic regression models were used to identify risk factors, reporting crude and adjusted odds ratios (OR, AOR) with 95% confidence intervals (CI). A p-value < 0.05 was considered significant. A total of 313 patients was included (median age: 34 years, range 24-41); 295 (94.2%) were newly diagnosed, and 16 (5.1%) were HIV-positive. Men accounted for 69% of cases, and the age group 24-44 was the most represented (55.9%). The median patient delay was 30 days (IQR 21-62), and 135 (43.1%) experienced prolonged delays. Multivariate analysis showed that residence in Mfilou district was associated with longer delays (OR = 2.77, 95%CI: 1.22-6.30; p = 0.004), whereas diabetes mellitus was linked to shorter delays (OR = 0.15, 95%CI: 0.02-1.13; p = 0.008). Although patient-related diagnostic delay was not significantly associated with treatment outcomes, patients with delays > 30 days had higher odds of death (OR = 2.30, 95%CI: 0.7-7.3) and treatment failure (OR = 5.4, 95%CI: 0.8-66.4). A high median patient-related diagnostic delay of 30 days was observed in Brazzaville. Residence in peripheral districts and diabetes mellitus status were significant predictors of delay. Although not statistically significant, prolonged patient delays tended to be associated with higher risks of death and treatment failure. Strengthening early case detection and promoting prompt healthcare-seeking and diagnosis among symptomatic individuals are critical for reducing TB diagnostic delays and improving treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.